½ÃÀ庸°í¼­
»óǰÄÚµå
1442855

½ÉÀåÀ絿±âÈ­Ä¡·á ½Ã½ºÅÛ ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2023-2031³â)

Cardiac Resynchronization Therapy Systems Market (Product Type: Cardiac Resynchronization Therapy Pacemaker and Cardiac Resynchronization Therapy Defibrillator) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Transparency Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 156 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

½ÉÀåÀ絿±âÈ­Ä¡·á ½Ã½ºÅÛ ½ÃÀå - º¸°í¼­ ¹üÀ§

TMRÀÇ ¼¼°è ½ÉÀåÀ絿±âÈ­Ä¡·á ½Ã½ºÅÛ ½ÃÀå º¸°í¼­´Â °ú°Å¿Í ÇöÀçÀÇ ¼ºÀå µ¿Çâ°ú 2023-2031³â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ÁöÇ¥¿¡ ´ëÇÑ ±ÍÁßÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ´Â ±âȸ¸¦ Á¶»çÇÕ´Ï´Ù. ÀÌ º¸°í¼­´Â 2017-2031³â ±â°£ µ¿¾È ¼¼°è ½ÉÀåÀ絿±âÈ­Ä¡·á ½Ã½ºÅÛ ½ÃÀåÀÇ ¼öÀÍÀ» Á¦°øÇϸç, 2023³âÀ» ±âÁØ ¿¬µµ·Î, 2031³âÀ» ¿¹Ãø ¿¬µµ·Î °£ÁÖÇÕ´Ï´Ù. ¶ÇÇÑ 2023-2031³â ¼¼°è ½ÉÀåÀ絿±âÈ­Ä¡·á ½Ã½ºÅÛ ½ÃÀåÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR %)µµ Á¦°øÇÕ´Ï´Ù.

ÀÌ º¸°í¼­´Â ±¤¹üÀ§ÇÑ ¿¬±¸¸¦ ÅëÇØ ÀÛ¼ºµÇ¾ú½À´Ï´Ù. 1Â÷ Á¶»ç¿¡¼­´Â ºÐ¼®°¡µéÀÌ ÁÖ¿ä ¿ÀÇǴϾ𠸮´õ, ¾÷°è ¸®´õ ¹× ¿ÀÇǴϾð ¸ÞÀÌÄ¿¸¦ ÀÎÅͺäÇÏ¿© ÁÖ¿ä ¿¬±¸ Ȱµ¿ÀÇ ´ëºÎºÐÀ» ¼öÇàÇßÀ¸¸ç, 2Â÷ Á¶»ç¿¡¼­´Â ½ÉÀåÀ絿±âÈ­Ä¡·á ½Ã½ºÅÛ ½ÃÀåÀ» ÀÌÇØÇϱâ À§ÇØ ÁÖ¿ä ±â¾÷ÀÇ Á¦Ç° ¹®Çå, ¿¬·Ê º¸°í¼­, º¸µµ ÀÚ·á ¹× °ü·Ã ¹®¼­ ÂüÁ¶¸¦ Æ÷ÇÔÇÕ´Ï´Ù.

ÀÌ º¸°í¼­´Â ¼¼°è ½ÉÀåÀ絿±âÈ­Ä¡·á ½Ã½ºÅÛ ½ÃÀåÀÇ °æÀï ȯ°æ¿¡ ´ëÇØ ÀÚ¼¼È÷ Á¶»çÇϰí ÀÖ½À´Ï´Ù. ¼¼°è ½ÉÀåÀ絿±âÈ­Ä¡·á ½Ã½ºÅÛ ½ÃÀå¿¡¼­ Ȱµ¿ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÌ È®ÀεǾúÀ¸¸ç, °¢ ±â¾÷Àº ´Ù¾çÇÑ ¼Ó¼º Ãø¸é¿¡¼­ ÇÁ·ÎÆÄÀϸµµÇ¾ú½À´Ï´Ù. ȸ»ç ÇÁ·ÎÇÊ, À繫 »óÅÂ, ÃÖ±Ù µ¿Çâ ¹× SWOT´Â ÀÌ º¸°í¼­¿¡ ¼Ò°³µÈ ¼¼°è ½ÉÀåÀ絿±âÈ­Ä¡·á ½Ã½ºÅÛ ½ÃÀå ±â¾÷ÀÇ ¼Ó¼ºÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå °¡Á¤°ú Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à : ¼¼°è ½ÃÀå

Á¦4Àå ½ÃÀå °³¿ä

  • ¼Ò°³
  • °³¿ä
  • ½ÃÀå ¿ªÇÐ
  • ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø(2017-2031³â)

Á¦5Àå Áß¿äÇÑ ÀλçÀÌÆ®

  • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
  • ÁÖ¿ä Á¦Ç°/ºê·£µå ºÐ¼®
  • ÁÖ¿ä ÀμöÇÕº´
  • COVID-19 ÆÒµ¥¹ÍÀÌ ¾÷°è¿¡ ¹ÌÄ¡´Â ¿µÇâ

Á¦6Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Á¦Ç° À¯Çüº°

  • ¼Ò°³¿Í Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú/¹ßÀü
  • ½ÃÀå ±Ý¾× ¿¹Ãø : Á¦Ç° À¯Çüº°(2017-2031³â)
    • ½ÉÀåÀ絿±âÈ­Ä¡·á ÆäÀ̽º¸ÞÀÌÄ¿
    • ½ÉÀåÀ絿±âÈ­Ä¡·á Á¦¼¼µ¿±â
  • ½ÃÀå ¸Å·Âµµ ºÐ¼® : Á¦Ç° À¯Çüº°

Á¦7Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀå ±Ý¾× ¿¹Ãø : Áö¿ªº°(2017-2031³â)
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ½ÃÀå ¸Å·Âµµ ºÐ¼® : Áö¿ªº°

Á¦8Àå ºÏ¹Ì ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦9Àå À¯·´ ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦11Àå ¶óÆ¾¾Æ¸Þ¸®Ä« ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦12Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦13Àå °æÀï »óȲ

  • ½ÃÀå ±â¾÷ : °æÀï ¸ÅÆ®¸¯½º(±â¾÷ °èÃþ¡¤±Ô¸ðº°)
  • ½ÃÀå Á¡À¯À² ºÐ¼® : ±â¾÷º°(2022³â)
  • ±â¾÷ °³¿ä
    • Medtronic
    • Boston Scientific Corporation
    • Abbott
    • LivaNova PLC
    • BIOTRONIK SE &Co. KG
    • Asahi Kasei Medical Co., Ltd.
    • NIHON KOHDEN CORPORATION
    • Schiller AG
ksm 24.04.15

Cardiac Resynchronization Therapy Systems Market - Scope of Report

TMR's report on the global cardiac resynchronization therapy systems market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cardiac resynchronization therapy systems market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cardiac resynchronization therapy systems market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cardiac resynchronization therapy systems market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cardiac resynchronization therapy systems market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cardiac resynchronization therapy systems market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cardiac resynchronization therapy systems market.

The report delves into the competitive landscape of the global cardiac resynchronization therapy systems market. Key players operating in the global cardiac resynchronization therapy systems market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cardiac resynchronization therapy systems market profiled in this report.

Key Questions Answered in Global cardiac resynchronization therapy systems Market Report:

  • What is the sales/revenue generated by cardiac resynchronization therapy systems across all regions during the forecast period?
  • What are the opportunities in the global cardiac resynchronization therapy systems market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Cardiac Resynchronization Therapy Systems Market - Research Objectives and Research Approach

The comprehensive report on the global cardiac resynchronization therapy systems market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cardiac resynchronization therapy systems market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cardiac resynchronization therapy systems market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cardiac Resynchronization Therapy Systems Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Cardiac Resynchronization Therapy Systems Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Cardiac Resynchronization Therapy Systems Market Analysis and Forecast, by Product Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Product Type, 2017-2031
    • 6.3.1. Cardiac Resynchronization Therapy Pacemaker
    • 6.3.2. Cardiac Resynchronization Therapy Defibrillator
  • 6.4. Market Attractiveness Analysis, by Product Type

7. Global Cardiac Resynchronization Therapy Systems Market Analysis and Forecast, by Region

  • 7.1. Key Findings
  • 7.2. Market Value Forecast, by Region, 2017-2031
    • 7.2.1. North America
    • 7.2.2. Europe
    • 7.2.3. Asia Pacific
    • 7.2.4. Latin America
    • 7.2.5. Middle East & Africa
  • 7.3. Market Attractiveness Analysis, by Region

8. North America Cardiac Resynchronization Therapy Systems Market Analysis and Forecast

  • 8.1. Introduction
  • 8.2. Key Findings
  • 8.3. Market Value Forecast, by Product Type, 2017-2031
    • 8.3.1. Cardiac Resynchronization Therapy Pacemaker
    • 8.3.2. Cardiac Resynchronization Therapy Defibrillator
  • 8.4. Market Value Forecast, by Country, 2017-2031
    • 8.4.1. U.S.
    • 8.4.2. Canada
  • 8.5. Market Attractiveness Analysis
    • 8.5.1. By Product Type
    • 8.5.2. By Country

9. Europe Cardiac Resynchronization Therapy Systems Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Key Findings
  • 9.3. Market Value Forecast, by Product Type, 2017-2031
    • 9.3.1. Cardiac Resynchronization Therapy Pacemaker
    • 9.3.2. Cardiac Resynchronization Therapy Defibrillator
  • 9.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 9.4.1. Germany
    • 9.4.2. U.K.
    • 9.4.3. France
    • 9.4.4. Italy
    • 9.4.5. Spain
    • 9.4.6. Rest of Europe
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Product Type
    • 9.5.2. By Country/Sub-region

10. Asia Pacific Cardiac Resynchronization Therapy Systems Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Product Type, 2017-2031
    • 10.3.1. Cardiac Resynchronization Therapy Pacemaker
    • 10.3.2. Cardiac Resynchronization Therapy Defibrillator
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. China
    • 10.4.2. Japan
    • 10.4.3. India
    • 10.4.4. Australia & New Zealand
    • 10.4.5. Rest of Asia Pacific
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Product Type
    • 10.5.2. By Country/Sub-region

11. Latin America Cardiac Resynchronization Therapy Systems Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Product Type, 2017-2031
    • 11.3.1. Cardiac Resynchronization Therapy Pacemaker
    • 11.3.2. Cardiac Resynchronization Therapy Defibrillator
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. Brazil
    • 11.4.2. Mexico
    • 11.4.3. Rest of Latin America
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Product Type
    • 11.5.2. By Country/Sub-region

12. Middle East & Africa Cardiac Resynchronization Therapy Systems Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Product Type, 2017-2031
    • 12.3.1. Cardiac Resynchronization Therapy Pacemaker
    • 12.3.2. Cardiac Resynchronization Therapy Defibrillator
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. GCC Countries
    • 12.4.2. South Africa
    • 12.4.3. Rest of Middle East & Africa
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Product Type
    • 12.5.2. By Country/Sub-region

13. Competition Landscape

  • 13.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 13.2. Market Share Analysis, by Company (2022)
  • 13.3. Company Profiles
    • 13.3.1. Medtronic
      • 13.3.1.1. Company Overview
      • 13.3.1.2. Product Portfolio
      • 13.3.1.3. SWOT Analysis
      • 13.3.1.4. Financial Overview
      • 13.3.1.5. Strategic Overview
    • 13.3.2. Boston Scientific Corporation
      • 13.3.2.1. Company Overview
      • 13.3.2.2. Product Portfolio
      • 13.3.2.3. SWOT Analysis
      • 13.3.2.4. Financial Overview
      • 13.3.2.5. Strategic Overview
    • 13.3.3. Abbott
      • 13.3.3.1. Company Overview
      • 13.3.3.2. Product Portfolio
      • 13.3.3.3. SWOT Analysis
      • 13.3.3.4. Financial Overview
      • 13.3.3.5. Strategic Overview
    • 13.3.4. LivaNova PLC
      • 13.3.4.1. Company Overview
      • 13.3.4.2. Product Portfolio
      • 13.3.4.3. SWOT Analysis
      • 13.3.4.4. Financial Overview
      • 13.3.4.5. Strategic Overview
    • 13.3.5. BIOTRONIK SE & Co. KG
      • 13.3.5.1. Company Overview
      • 13.3.5.2. Product Portfolio
      • 13.3.5.3. SWOT Analysis
      • 13.3.5.4. Financial Overview
      • 13.3.5.5. Strategic Overview
    • 13.3.6. Asahi Kasei Medical Co., Ltd.
      • 13.3.6.1. Company Overview
      • 13.3.6.2. Product Portfolio
      • 13.3.6.3. SWOT Analysis
      • 13.3.6.4. Financial Overview
      • 13.3.6.5. Strategic Overview
    • 13.3.7. NIHON KOHDEN CORPORATION
      • 13.3.7.1. Company Overview
      • 13.3.7.2. Product Portfolio
      • 13.3.7.3. SWOT Analysis
      • 13.3.7.4. Financial Overview
      • 13.3.7.5. Strategic Overview
    • 13.3.8. Schiller AG
      • 13.3.8.1. Company Overview
      • 13.3.8.2. Product Portfolio
      • 13.3.8.3. SWOT Analysis
      • 13.3.8.4. Financial Overview
      • 13.3.8.5. Strategic Overview
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦